Cancer Cell International (Oct 2023)

Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer

  • Jiani Yang,
  • Chao Wang,
  • Yue Zhang,
  • Shanshan Cheng,
  • Meixuan Wu,
  • Sijia Gu,
  • Shilin Xu,
  • Yongsong Wu,
  • Jindan Sheng,
  • Dominic Chih-Cheng Voon,
  • Yu Wang

DOI
https://doi.org/10.1186/s12935-023-03040-3
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 20

Abstract

Read online

Abstract Ovarian cancer (OV) is the most lethal gynecological malignancies worldwide. The coagulation cascade could induce tumor cell infiltration and contribute to OV progression. However, coagulation-related gene (CRG) signature for OV prognosis hasn’t been determined yet. In this study, we evaluated the prognostic value of coagulation scores through receiver operating characteristics (ROC) analysis and K-M curves, among OV patients at our institution. Based on the transcriptome data of TCGA-OV cohort, we stratified two coagulation-related subtypes with distinct differences in prognosis and tumor immune microenvironment (p < 0.05). Moreover, from the 6406 differentially-expressed genes (DEGs) between the GTEx (n = 180) and TCGA-OV cohorts (n = 376), we identified 138 potential CRGs. Through LASSO-Cox algorithm, we finally distinguished a 3-gene signature (SERPINA10, CD38, and ZBTB16), with promising prognostic ability in both TCGA (p < 0.001) and ICGC cohorts (p = 0.040). Stepwise, we constructed a nomogram based on the clinical features and coagulation-related signature for overall survival prediction, with the C-index of 0.6761, which was evaluated by calibration curves. Especially, based on tissue microarrays analysis, Quantitative real-time fluorescence PCR (qRT-PCR), and Western Blot, we found that aberrant upregulation of CRGs was related to poor prognosis in OV at both mRNA and protein level (p < 0.05). Collectively, the coagulation-related signature was a robust prognostic biomarker, which could provide therapeutic benefits for chemotherapy/immunotherapy and assist clinical decision in OV patients.

Keywords